Aandeel HOOK HOOKIPA PHARMA INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen HOOKIPA Pharma Inc.

Aandelen

HOOK

US43906K1007

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 25-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,8061 USD -5,16% Intraday-grafiek van HOOKIPA Pharma Inc. +5,39% -0,48%
25/04 Transcript : HOOKIPA Pharma Inc. - Special Call
25/04 HOOKIPA Pharma Inc. kondigt Pivotal Fase 2/3 studieontwerp aan voor HB-200 in combinatie met pembrolizumab CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
HOOKIPA Pharma Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(4)
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
North American Morning Briefing : Stocks Struggle After New Records
North American Morning Briefing : Stock Futures -2-
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers HOOK
  4. Nieuws HOOKIPA Pharma Inc.
  5. Andere talen